A federal judge ruled that Alexion, AstraZeneca’s subsidiary, is immune from an antitrust lawsuit alleging it used patents to delay Soliris biosimilars. The complaint estimated purchasers overpaid by more than $2 billion; AstraZeneca reported more than $1.8 billion in Soliris revenue last year.
U.S. District Judge Brian Murphy ruled that Alexion was immune from claims brought by health plan EmblemHealth on behalf of U.S. Soliris purchasers. The judge rejected EmblemHealth’s argument that the immunity doctrine did not apply because Alexion had allegedly brought sham litigation to enforce its patents.
EmblemHealth alleged that Alexion improperly obtained new patents to block Soliris biosimilars for four years after its original patents expired, and used the patents to extract settlements from competitors. The complaint said the alleged conduct delayed biosimilars until March 2025 at the earliest and caused overpayments estimated to exceed $2 billion. AstraZeneca reported more than $1.8 billion in Soliris revenue last year; the drug treats rare blood disorders. EmblemHealth said it was reviewing the decision and would determine any appropriate next steps.